Myelodysplastic syndromes

Critical Reviews in Oncology/Hematology

Volumn 23, Issue 1, 1996, Pages 57-93

  San Miguel, Jesús F ^a   Sanz, Guillermo F ^b   Vallespí, Teresa ^c   Del Cañizo, María C ^a   Sanz, Miguel A ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; AZACITIDINE; CALCITRIOL; CISPLATIN; CORTICOSTEROID; CYTARABINE; DANAZOL; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEME ARGINATE; HEXAMETHYLENEBISACETAMIDE; HOMOHARRINGTONINE; IDARUBICIN; IMMUNOMODULATING AGENT; INTERFERON; ISOTRETINOIN; PREDNISONE; PYRIDOXINE; RETINOID; THYMOCYTE ANTIBODY;

CYTOGENESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOLECULAR GENETICS; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; PROGNOSIS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029950704     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00197-7     Document Type: Review

References (458)

1. Sanz GF, Sanz MA, Vallespí T et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74:395-408, 1989.
2. Fenaux P, Preudhomme C, Stnestienne MH et al. De novo myelodysplastic syndromes in adults aged 50 or less: a report on 37 cases. Leuk Res 14:1053-1059, 1990.
3. Hamblin TJ, Oschier DG. The myelodysplastic syndrome - A practical guide. Hematol Oncol 5:19-34, 1987.
4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (FAB Co-operative Group). Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982.
5. Foucar K, Langdon RM, Armitage JO, Olson DB, Caroll TJ. Myelodysplastic syndromes: a clinic and pathologic analysis of 109 cases. Cancer 56:553-561, 1985.
6. May SJ, Smith SA, Jacobs A, Williams A, Bailey-Wood R. The myelodysplastic syndrome: analysis of laboratory characteristic in relation to the FAB classification. Br J Haematol 59:311-319, 1985.
7. Vallespi T, Torrabadella M, Juliá A et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol 61:83-92, 1985.
8. Paquette RL, Landau EM, Pierre RV et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82:590-599, 1993.
9. Jonveaux Ph, Fenaux P, Quiquandon I et al. Mutations in the p53 gene in myelodysplastic syndromes. Oncogene 6:2243-2247, 1991.
10. Mecucci C, Van Orshoven A, Vermaelen K et al. 11q-chromosome is associated with abnormal iron stores in myelodysplastic syndromes. Cancer Genet Cytogenet 27:39-44, 1987.
11. Raymakers R, De Witte T, Loziasse J, Van der Lely N, Boezeman J, Haanen C. In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukemia. Br J Haematol 78:35-41, 1991.
12. Francis GE, Miller EJ, Wonke B, Wing MA, Berney JJ, Hoffbrand AV. Use of bone marrow culture in prediction of acute leukemic transformation in preleukemia. Lancet 1:1409-1410, 1983.
13. San Miguel JF, Hernandez JM, Gonzalez-Sarmiento R et al. Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic and clinical characteristics. Blood 78:768-774, 1991.
14. List AF, Garewal HS, Sandberg AA. The myelodysplastic syndromes: biology and implications for management. J Clin Oncol 8:1424-1441, 1990.
15. Cheson BD. Chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Oncol, 19:85-94, 1992.
16. Rhoads CP, Barker WH. Refractory anemia: analysis of 100 cases. J Am Med Assoc 110:794-796, 1938.
17. Björkman SE. Chronic refractory anemia with sideroblastic bone marrow. A study of four cases. Blood 11:250-259, 1956.
18. Dreyfus B, Rochant H, Sultan C, Clauvel JP, Yvart J, Chesneau AM. Les anémies réfractaires avec excès de myéloblastes dans la moelle. Étude de 11 observations. Presse Médicale 78:359-364, 1970.
19. Miescher PA, Farquet JJ. Chronic myelomonocytic leukemia in adults. Semin Hematol 11:129-139, 1974.
20. Geary CG, Catovsky D, Wiltshaw E et al. Chronic myelomonocytic leukaemia. Br J Haematol 30:289-302, 1975.
21. Block M, Jacobson LO, Bethard WF. Preleukemic acute human leukemia. J Am Med Assoc 152:1018-1023, 1953.
22. Rheingold JJ, Kaufman R, Adelson E, Lear A. Smouldering acute leukemia. New Engl J Med 268:812-815, 1963.
23. Van der Weide M, Sizoo W, Krefft J, Langenhuisen MMAC. Myelodysplastic syndromes: analysis of morphological features related to the FAB-classification. Eur J Haematol 41:58-61, 1988.
24. Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E. Natural history of idiopathic refractory sideroblastic anemia. Blood 71:305-312, 1988.
25. Goasguen JE, Bennett JM. Classification and morphologic features of the myelodysplastic syndromes. Semin Oncol 19:4-13, 1992.
26. Bennett JM. Classification of the myelodysplastic syndromes. Clin Haematol 15:909-923, 1986.
27. Doll DC, List LF, Dayhoff DA, Loy TS, Ringenberg QS, Yarbro JW. Acanthocytosis associated with myelodysplasia. J Clin Oncol 7:1569-1572, 1989.
28. Bessis MC, Jensen WN. Sideroblastic anemia, mitochondria and erythroblastic iron. Br J Hematol 11:49-51, 1965.
29. Jaén A, Irriguible D, Millá F et al. Abnormal chromatin clumping in leucocytes: a clue to a new subtype of myelodysplastic syndrome. Eur J Haematol 45:209-214, 1990.
30. Langenhuisen MMAC. Neutrophils with ring-shaped nuclei in myeloproliferative disease. Br J Haematol 58:227-230, 1984.
31. Kawaguchi M, Nehashi Y, Aizawa S, Toyama K. Comparative study of immunocytochemical staining versus Giemsa stain for detecting dysmegakaryopoiesis in myelodysplastic syndromes. Eur J Haematol 44:89-93, 1990.
32. Sokal G, Michaux JL, van der Berghe H et al. New hematological syndrome with a distinct karyotype: The 5q-chromosome. Blood 46:519-523, 1975.
33. Mathew P, Tefferi A, Dewald GW et al. The 5q-syndrome: a new single institution study of 43 consecutive patients. Blood 81:1040-1045, 1993.
34. Rios A, Caǹizo MC. Sanz MA et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 75:26-33, 1990.
35. Tricot G, de Wolf-Peeters C, Hendricx B, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. I Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol 57:423-430, 1984.
36. Tricot G, de Wolf-Peeters C, Vlientinck R, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 58:217-225, 1984.
37. Lambertenghi-Delilliers G, Orazi A, Luksch R, Annaloro C, Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 78:161-166, 1991.
38. Sultan C, Sigaux F, Imbert M et al. Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol 49:11-16, 1981.
39. Kouides PA, Bennett JM. Morphology and classification of myelodysplastic syndromes. Hematol Oncol Clin North Am 6:485-499, 1992.
40. Galton DAG. The myelodysplastic syndromes. Scand J Haematol 36(Suppl 45): 11-20, 1986.
41. Hast R. Sideroblasts in myelodysplasia: their nature and clinical significance. Scand J Haematol 36(Suppl 45):53-55, 1986.
42. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 74:45-52, 1990.
43. Sanz GF, Sanz MA, Vallespí T, del Cañizo MC. Two types of acquired idiopathic sideroblastic anaemia. Br J Haematol 75:633-634, 1990.
44. Vallespí T, López F, Sanz G et al. Refractory anaemia with ring sideroblasts (RAS): a simple scoring system based on easily available parameters. Leuk Res 15(Suppl):18, 1991.
45. Seigneurin D, Audhuy B. Auer rods in refractory anemia with excess of blasts: presence and significance. Am J Clin Pathol 80:359-362, 1983.
46. Öst Å, Reizenstein P. Minimal diagnostic criteria for the myelodysplastic syndrome. Leuk Res 16:9-11, 1992.
47. Vallespí T, Sanz G, Torrabadella M, Irriguible D, Sanz MA. Auer rods in myelodysplastic syndromes (MDS): presence and significance. Blood 76(Suppl 1):330a, 1990.
48. Ribera JM, Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myelomonocytic leukaemia according to the FAB criteria. Br J Haematol 65:307-311, 1987.
49. Fenaux P, Beuscart R, Lai JL et al. Prognostic factors in adult chronic myelomonocytic leukaemia: an analysis of 107 cases. J Clin Oncol 6:1417-1424, 1988.
50. Bennett JM, Catovsky D, Daniel MT et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Br J Haematol 87: 746-754, 1994.
51. Del Cañizo MC, Sanz G, San Miguel JF et al. Chronic myelomonocytic leukemia-clinicobiological characteristics: a multivariate analysis in a series of 70 cases. Eur J Haematol 42:466-473, 1989.
52. Shepherd PCA, Ganesan TS, Galton DAG. Haematological classification of the chronic myeloid leukaemias. In: Goldman JM, ed. Chronic Myeloid Leukaemia. Bailliere's Clinical Haematology, Vol 1. London: Bailliere Tindall, 1987, 887-905.
53. Martiat P, Michaux JL, Rodhain J et al. Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. Blood 78:205-211, 1991.
54. Estrov Z, Grunberger T, Chan HSL et al. Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. Blood 67:1382-1387, 1986.
55. Gualtieri RJ, Castleberry RP, Gibbons J et al. Cell culture studies in oncogene expression in juvenile chronic myelogenous leukemia. Exp Hematol 16:613-619, 1988.
56. Florensa L, Woessner S, Lafuente R et al. In vitro granulopoiesis in myelodysplastic syndromes (MDS) according to the FAB classification. Blut 56:C20, 1988.
57. Verwilghen RL, Boogaerts MA. The myelodysplastic syndromes. Blood Rev 1:34-43, 1987.
58. Kampmeier P, Anastasi J, Vardiman JW. Issues in the pathology of the myelodysplastic syndromes. Hematol Oncol Clin North Am 6:501-522, 1992.
59. Coiffier B, Adeleine P, Viala JJ, Byron P, Fiere D, Gentilhomme O, Vuvan H. Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients. Cancer 52:83-90, 1983.
60. Delacrétaz F, Schmidt PM, Piguet D, Bachmann F, Costa J. Histopathology of myelodysplastic syndromes. Am J Clin Pathol 87:180-186, 1987.
61. Yoshida Y, Oguma H, Maekawa T. Refractory myelodysplastic anaemias with hypocellular bone marrow. J Clin Pathol 41:763-767, 1988.
62. Kitagawa M, Kamiyama R, Takemura T, Kasuga T. Bone marrow analysis of the myelodysplastic syndromes: histological and immuno-histological features related to the evolution of overt leukemia. Virchows Arch 57:47-53, 1989.
63. Maschek H, Kaloutsi V, Rodriguez-Kaiser M, Werner M, Choritz H, Mainzer K, Dietzfelbinger M, Georgii A. Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics and prognosis. Ann Hematol 66:117-122, 1993.
64. Nand S, Godwin JE. Hypoplastic myelodysplastic syndrome. Cancer 62:958-964, 1988.
65. Fohlmeister I, Fischer R, Mödder B et al. Aplastic anaemia and the hypocellular myelodysplastic syndrome: histomorphological, diagnostic, and prognostic features. J Clin Pathol 38:1218-1224, 1985.
66. Appelbaum FR, Barrall J, Storb R et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 15:1134-1139, 1987.
67. Imbert M, Nguyen D, Sultan C. Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis. Leuk Res 16:51-54, 1992.
68. Pagliuca A, Layton DM, Manoharan A et al. Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Br J Haematol 71:499-504, 1989.
69. Felman P, Bryon PA, Gentilhomme O et al. The syndrome of abnormal chromatin clumping in leucocytes: a myelodysplastic disorder with proliferative features? Br J Haematol 70:49-52, 1988.
70. Hasle H, Brock BJ, Pederson NT. Myelodysplastic syndromes in childhood: a population based study on nine cases. Br J Haematol 81:495-498, 1992.
71. Jackson GH, Carey PJ, Cant AJ, Bown NP, Reid MM. Myelodysplastic syndromes in children. Br J Haematol 84:185-186, 1993.
72. Tuncer MA, Pagliuca A, Hicsonmez G, Yetgin S, Ozsoylu S, Mufti GJ. Primary myelodysplastic syndrome in children: the clinical experience in 33 cases. Br J Haematol 82:347-353, 1992.
73. Chessels JM. Myelodysplasia. Clin Hematol 4:459-482, 1991.
74. Nair R, Athale UA, Iyer RS et al. Childhood myelodysplastic syndromes: clinical features, cytogenetics and prognosis. Indian J Pediatr 59:443-448, 1992.
75. Brandwein JM, Horsman DE, Eaves AC, Eaves CJ, Massing BG, Wasworth LD, Rogers PCJ, Kalousek DK. Childhood myelodysplasia: suggested classification as myelodysplastic syndromes based on laboratory and clinical findings. Am J Pediatr Hematol Oncol 12:63-70, 1990.
76. Creutzig U, Cantú-Rajnoldi A, Ritter J, Romitti L, Odenwald E, Conter V, Riehn H, Massera G. Myelodysplastic syndromes in childhood. Am J Pediatr Hematol Oncol 9:324-330, 1987.
77. Guinan EC, Tarbell NJ, Tantravahi R, Weinstein HJ. Bone marrow transplantation for children with myelodysplastic syndromes. Blood 73:619-622, 1989.
78. Gadner H, Haas OA. Experience in pediatric myelodysplastic syndromes. Hematol Oncol Clin North Am 6:655-672, 1992.
79. Mecucci C, Van den Berghe H. Cytogenetics. Hematol Oncol Clin North Am 6:523-541, 1992.
80. Third MIC Cooperative Study Group: Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Cancer Genet Cytogenet 32:1-10, 1988.
81. Third National Cancer Survey. Cutler S, Young J, eds. Incidence data. Natl Cancer Inst Monogr 41:10, 1975.
82. Baccarani M, Bosi A, PaPa G. Writing Committee for the GIGI, Ghirotti Task Force for Malignant Lymphoma: second malignancy in patients treated for Hodgkin's disease. Cancer 46:1735-1740, 1980.
83. Valagussa P, Santoro A, Fossati Bellani F, Franchi F, Banfi A, Bonadona G. Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. Blood 59:488-494, 1982.
84. Vose J, Darrington D, Bierman P et al. Proceedings of Fifth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 9-12, 1993, 42 pp.
85. Brusamolino E, Bernasconi C. Therapy-related myelodysplastic syndromes and acute leukemias. Leukemia 6(Suppl 4): 23-25, 1992.
86. Dohy H, Genot J, Imbert M et al. Myelodysplasia and leukemia related to chemotherapy and/or radiotherapy: a hematological study of 13 cases. Value of macrocytosis as an early sign of bone marrow injury. Clin Lab Haematol 2:111-119, 1980.
87. Vardiman J, Golomb H, Rowley J, Variakojis D. Acute nonlymphocytic leukemia in malignant lymphoma: a morphologic study. Cancer 42:229-242, 1978.
88. Bennett JM, Moloney WC, Greene MH et al. Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents. Hematol Pathol 1:99-104, 1987.
89. Rowley JD, Golomb H, Vardiman J. Nonrandom chromosomal abnormalities in acute non-lymphocytic leukemia in patients treated for Hodgkin's disease and non-Hodgkin's lymphomas. Blood 50:759-770, 1977.
90. Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphological study of 65 cases. Blood 65:1364-1372, 1985.
91. Rosenbloom B, Schreck R, Koeffler P. Therapy related myelodysplastic syndromes. Hematol Oncol Clin North Am 6:707-722, 1992.
92. Zhao L, van Oort J, Cork A, Liang JC. Comparison between interphase and metaphase cytogenetics in detecting chromosome 7 defects in hematological neoplasias. Am J Hematol 43:205-211, 1993.
93. Kibbelaar RE, van Kamp H, Dreef EJ et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 79:1823-1828, 1992.
94. Pérez-Losada A, Wessman M, Tiainen M et al. Trisomy 12 in chronic lymphocytic leukemia: an interphase cytogenetic study. Blood 78:775-779, 1991.
95. Chen Z, Morgan R, Berger CS, Sandberg AA. Application of fluorescence in situ hybridization in hematological disorders. Cancer Genet Cytogenet 63:62-69, 1992.
96. Anastasi J, Feng J, Le Beau MM et al. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood 81:1580-1585, 1993.
97. Noël P, Tefferi A, Píerre RV, Jenkins RB, Deswald GW. Karyotypic analysis in primary myelodysplastic syndromes. Blood Rev 7:10-18, 1993.
98. Gerritsen WR, Donohue J, Bauman J et al. Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization. Blood 80:217-224, 1992.
99. Mufti GJ. Chromosomal deletions in the myelodysplastic syndrome. Leuk Res 16:35-41, 1992.
100. Horiike S, Taniwaki M, Misawa S et al. Chromosome abnormalities and karyotypic evolution in 83 patients with myelodysplastic syndrome and predictive value for prognosis. Cancer 62:1129-1138, 1988.
101. Nowell PC. Chromosome abnormalities in myelodysplastic syndrome. Semin Oncol 19:25-33, 1992.
102. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of No. 5 chromosome. Nature 251:437-438, 1974.
103. Mathew P, Tefferi A, Goldberg SL, Dewald GW, Hoagland HC, Nöel P. The '5q-syndrome': a single institution study of 43 consecutive patients. Blood 78(Suppl):35a, 1991.
104. Van den Berghe H, Vermaelen K, Mecucci C et al. The 5q-anomaly. Cancer Genet Cytogenet 17:189-255, 1985.
105. Kroef MJPL, Fibbe WE, Mout R et al. Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. Blood 81:1849-1854, 1993.
106. Pedersen B. Jensen IM. Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients. Leukemia 5:566-573, 1991.
107. Boultwood J, Rack K, Kelly S et al. Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion. Proc Natl Acad Sci USA 88:6176-6180, 1991.
108. Le Beau MM, Lemons RS, Espinosa R, Larson RA, Arai N, Rowley JD. Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemia with a del(5q). Blood 73:647-650, 1989.
109. Paul B, Reid MM, Davidson EV et al. Familial myelodysplasia: progressive disease associated with emergence of monosomy 7. Br J Haematol 65:321-323, 1987.
110. Gahmberg CG, Andersson LC, Ruutu P et al. Decrease of the major high molecular weight surface glycoprotein of human granulocytes in monosomy-7 associated with defective chemotaxis. Blood 54:401-406, 1979.
111. Kere J, Ruutu T, Davies KA et al. Chromosome 7 long arm deletion in myeloid disorders: a narrow breakpoint region in 7q22 denned by molecular mapping. Blood 73:230-234, 1989.
112. Collyn-d'Hooghe M, Fenaux P, Lai JL, Bauters F, Loucheux-Lefebvre MH, Kerckaert JP. Absence of rearrangement of proto-oncogene MET in 88 cases of myelodysplastic syndromes (MDS). Br J Haematol 73:40-42, 1989.
113. Solé F, Prieto F, Badía L et al. Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genet Cytogenet 64:12-20, 1992.
114. Vallespí T, Sanz G, Pujol A et al. Karyotype analysis in 181 primary myelodysplastic syndromes (MDS). Blood 82(Suppl 1):557a, 1993.
115. Vallespí T, Pujol A, Irriguible D. Trisomy 8 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Blood 80(Suppl 1):462a, 1992.
116. Yunis JJ, Lobell M, Arnesen MA et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndromes and acute myelogenous leukaemia. Br J Haematol 68:189-194, 1988.
117. Weh HJ, Kuse R, Hossfeld DK. Acute nonlymphocytic leukemia (ANLL) with isochromosome i(17q) as the sole chromosomal anomaly: a distinct entity? Eur J Haematol 44:312-314, 1990.
118. 1-negative leukemia: a clinical, cytogenetic, and molecular study. Blood 75:1679-1683, 1990.
119. Solé F, Torrabadella M, Granada I. Isochromosome 17q as a sole anomaly: a distinct myelodysplastic syndrome entity? Leuk Res 17:717-720, 1993.
120. Baker SJ, Preisinger AC, Jessup JM et al. P53 mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7712-7722, 1990.
121. Group Francais de Cytogénétique Hématologique. Cytogenetics of chronic myelomonocytic leukemia. Cancer Genet Cytogenet 21:11-30, 1986.
122. Sakaguchi AY, Zabel BU, Grzeschik KH et al. Regional localization of two human cellular Kirsten ras genes on chromosomes 6 and 12. Mol Cell Biol 4:989-993, 1985.
123. Pierre RV, Hoagland HC. Age-associated ancuploidy: loss of Y chromosome from human bone marrow cells with aging. Cancer 30:889-894, 1972.
124. Estey E, Trujillo JM, Cork A et al. AML-associated cytogenetic abnormalities (inv(16), del(16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol 6:43-48, 1992.
125. Smadja N, Krulik M, Hagemeijer A, van der Plas DC, González Canali G, de Gramont A. Cytogenetic and molecular studies of the Philadelphia translocation t(9;22) observed in a patient with myelodysplastic syndrome. Leukemia 3:236-238, 1989.
126. 1 chromosome in myelodysplasia: cytogenetic and molecular studies. Leuk Lymphoma 6:401-406, 1992.
127. Vila L, Charrin C, Archimbaud E et al. Correlation between cytogenetics and morphology in myelodysplastic syndromes. Blut 60:223-227, 1990.
128. Dewald GW, Brecher M, Travis LB, Stupca PJ. Twenty-six patients with hematologic disorders and X chromosome abnormalities: frequent i dic(X)(q13) chromosomes and Xq 13 anomalies associated with pathologic ringed sideroblasts. Cancer Genet Cytogenet 42:173-186, 1989.
129. Davis MP, Dewald GW, Pierre RV, Hoagland HC. Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genet Cytogenet 12:63-71, 1984.
130. Tenth International Workshop on Human Gene Mapping. Human gene mapping 10. Cytogenet Cell Genet 51:1-1147, 1989.
131. Ohyashiki K, Murakami T, Ohyashiki JH et al. Double 20q-anomaly in myelodysplastic syndrome. Cancer Genet Cytogenet 58:174-176, 1992.
132. Moormeier JA, Rubin CM, Le Beau MM et al. Trisomy 6: a recurring cytogenetic abnormality associated with marrow hypoplasia. Blood 77:1397-1401, 1991.
133. Lai JL, Zandecki M, Fenaux P et al. Translocations (5;17) and (7;17) in patients with de novo or therapy-related myelodysplastic syndromes or acute nonlymphocytic leukemia. A possible association with acquired pseudo-Pelger-Hüet anomaly and small vacuolated granulocytes. Cancer Genet Cytogenet 46:173-184, 1990.
134. Heim S. Cytogenetic findings in primary and secondary MDS. Leuk Res 16:43-46, 1992.
135. Pedersen-Bjergaard J, Philip P. Balanced translocations involving chromosome ends 11q23 and 21q22 are highly characteristic for myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 78:1147-1148, 1991.
136. Rubin CM, Arthur DC, Woods WG et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood 78:2982-2988, 1991.
137. Suciu S, Kuse R, Weh HJ, Hossfeld DK. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with the novo myelodysplastic syndrome. Cancer Genet Cytogenet 44:15-26, 1990.
138. Geddes AD, Bowen DT, Jacobs A. Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. Br J Haematol 76:194-202, 1990.
139. Sixth International Workshop on Chromosomes in Leukemia 1987. Clinical-cytogenetics correlations in myeloid dysplasia (preleukemia): Report of the Sixth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 40:149-161, 1989.
140. Pierre RV, Catovsky D, Mufti GJ et al. Clinical-cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 40:149-161, 1989.
141. Gold EF, Conjalka M, Pelus LM. Marrow cytogenetic and cell-culture analysis of myelodysplastic syndromes: insights to pathophysiology and prognosis. J Clin Oncol 1:627-634, 1983.
142. White AD, Culligan DJ, Hoy TG, Jacobs A. Extended cytogenetic follow-up of patients with myelodysplastic syndrome (MDS). Br J Haematol 81:499-502, 1992.
143. Heim S, Mitelman F. Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol 15:1003-1021, 1986.
144. Jacobs RH, Cornbleet MA, Vardiman JW, Larson RA, Le Beau MM, Rowley JD. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 67:1765-1772, 1986.
145. Fonatsch C, Haase D, Freund M, Bartels, Tesch H. Partial trisomy 1q. A nonrandom primary chromosomal abnormality in myelodysplastic syndromes?. Cancer Genet Cytogenet 56:243-253, 1991.
146. Musilova J, Michalova K. Chromosome study of 85 patients with myelodysplastic syndrome. Cancer Genet Cytogenet 33:39-50, 1988.
147. Toyama K, Ohyashiki K, Yoshida Y et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia 7:499-508, 1993.
148. Morel P, Hebbar M, Lai JL et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7:1315-1323, 1993.
149. Raskind WH, Tirumali N, Jacobsen R et al. Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 63:1318-1323, 1984.
150. Gilliland DG, Blanchard KL, Levy J et al. Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA 88:6848-6852, 1991.
151. Janssen JWG, Buschle M, Layton M et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 73:248-254, 1989.
152. Tefferi A, Thibodeau SN, Solberg Jr LA. Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphism. Blood 75:1770-1773, 1990.
153. Tsukamoto N, Morita K, Maehara T et al. Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. Br J Haematol 83:589-594, 1993.
154. Abrahamsom G, Boultwood J, Madden J et al. Clonality of cell populations in refractory anemia anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses. Br J Haematol 79:550-555, 1991.
155. Van Kamp H, de Pijper G, Verlaan de Vries M et al. Longitudinal analysis of point mutations of the N-ras protooncogen in patients with myelodysplasia using achieved blood smears. Blood 79:1266-1270, 1992.
156. Culligan DJ, Cachia P, Whittaker J, Jacobs A, Padua RA. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 81:346-352, 1992.
157. Hirsch-Ginsberg C, Le Maistre AC, Kantarjian H et al. RAS mutations are rare events in Philadelphia chromosome-negative/ber gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76:1214-1219, 1990.
158. Jacobs A. Genetic abnormalities in myelodysplastic syndrome. Cancer Genet Cytogenet 56:1-6, 1991.
159. Lyons J, Janssen JWG, Bartram CR et al. Mutations of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood 71:1707-1712, 1988.
160. Melani C, Haliassos A, Chomel JC et al. Ras activation in myelodysplastic syndromes: clinical and molecular study of the chronic phase of the disease. Br J Haematol 74:408-413, 1990.
161. Padua RA, Carter G, Hughes D et al. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia 2:503-510, 1988.
162. Pedersen-Bjergaard J, Janssen JWG, Lyons J et al. Point mutation of the ras protooncogenes and chromosome aberration in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents. Cancer Res 48:1812-1817, 1988.
163. Yunis JJ, Boot AJM, Mayer MG et al. Mechanisms of ras mutations in myelodysplastic syndromes. Oncogene 4: 609-614, 1989.
164. Bartram CR. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 65:557-570, 1992.
165. Hirai H, Okada M, Mizoguchi H et al. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood 71:256-258, 1988.
166. List AF, Jacobs A. Biology and pathogenesis of myelodysplastic syndromes. Semin Oncol 19:14-24, 1992.
167. Nakagawa T, Saitoh S, Imoto S et al. Loss of multiple point mutations of ras genes associated with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br J Haematol 77:250-252, 1991.
168. Sherr CJ. Colony-stimulating factor-1 receptor. Blood 75:1-12, 1990.
169. Ridge SA, Worwood M, Oscier D et al. FMS mutations in myelodysplastic, leukemic and normal subjects. Proc Natl Acad Sci USA 87:1377-1138, 1990.
170. Tobal K, Pagliuca A, Bhatt B et al. Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 4:486-489, 1990.
171. Carter G, Hughes DC, Clark RE et al. RAS mutations in patients following cytotoxic therapy for lymphoma. Oncogene 5:411-416, 1990.
172. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 351:453-456, 1991.
173. Ludwig L, Schulz AS, Janssen JWG, Grünewald K, Bartram CR. p53 mutations in myelodysplastic syndromes. Leukemia 6:1302-1304, 1992.
174. Sugimoto K, Hirano N, Toyoshima H et al. Mutation of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 81:3022-3026, 1993.
175. Fenaux P, Jonveaux P, Quiquandon I et al. p53 gene mutations in myeloid leukemia with 17p monosomy. Blood 78:1652-1656, 1991.
176. Soekarman D, Von Lindern M, Dalnen S et al. The translocation (6;9)(p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood 79:2990-2977, 1992.
177. Botnick LE, Hannon EC, Obbagy J et al. Variation of hemato-poietic stem cell self-renewal capacity as a function of age: further evidence for heterogeneity of the stem cell compartment. Blood 60:268-271, 1982.
178. Lipschitz DA, Udupa KB, Milton KY et al. Effect of age on hematopoiesis in man. Blood 63:502-509, 1984.
179. Greenberg P. In vitro marrow culture studies in myelodysplastic syndromes. Semin Oncol 19:34-46, 1992.
180. Chui DH, Clark BJ. Abnormal erythroid progenitor cells in human preleukemia. Blood 60:362-367, 1982.
181. Greenberg PL. The smoldering myeloid leukemic states: clinical and biologic features. Blood 61:1035-1044, 1983.
182. Juvonen E, Partanen S, Knuutila S et al. Megakaryocyte colony formation by bone marrow progenitors in myelodysplastic syndromes. Br J Haematol 63:331-334, 1985.
183. Geissler K, Hinterberger W, Bettelheim P. Colony growth characteristics in chronic myelomonocytic leukemia. Leuk Res 12:373-377, 1988.
184. Michaux JL, Martiat P. Chronic myelomonocytic leukaemia (CMML) - A myelodysplastic or myeloproliferative syndrome? Leuk Lymphoma 9:35-41, 1993.
185. Sullivan SA, Marsden KA, Lowenthal RM, Jupe DM, Jones ME. Circulating CD34 + cells: an adverse prognostic factor in the myelodysplastic syndromes. Am J Hematol 39:96-101, 1992.
186. Backs B, Breeders L, Tow I, Löwenberg B. Blast colony-forming cells in myelodysplastic syndrome: decreased potential to generate erythroid precursors. Leukemia 7:75-79, 1993.
187. Carbonell F, Heimpel H, Kubanek B, Fliedner TM. Growth and cytogenetic characteristics of bone marrow colonies from patients with 5q-syndrome. Blood 66:463-465, 1985.
188. Greenberg PL, Mara B. The preleukemic syndrome: correlation of in vitro parameters of granulopoiesis with clinical features. Am J Med 66:951-958, 1979.
189. Verma DS, Spitzer G, Dicke KA. In vitro agar culture patterns in preleukemia and their clinical significance. Leuk Res 31:41-49, 1979.
190. Gold EJ, Mertelsmann RH, Itri LM et al. Phase I clinical trial of 13-cis retinoid acid in myelodysplastic syndromes. Cancer Treat Rep 67:981-986, 1983.
191. Guyotat D, Campos L, Thomas X et al. Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns. Am J Hematol 34:26-31, 1990.
192. Schipperus MR, Hagemeijer A, Ploemacher RE et al. Myelodysplastic syndromes progression to leukemia is directly related to PHA dependency for colony formation and independent of in vitro maturation capacity. Leukemia 2:433-437, 1988.
193. Aul C, Gattermann N, Schneider W. Comparison of in vitro growth characteristics of blast cell progenitors (CFU-L) in patients with myelodysplastic syndromes and acute myeloid leukemia. Blood 80:625-633, 1992.
194. Merchav S, Wagemaker G, Souza LM, Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 5:340-346, 1991.
195. Nagler A, Ginzton N, Negrin N, Bang D, Donlon T, Greenberg P. Effects of recombinant human granulocyte colony stimulating factor on in vitro hemopoiesis in the myelodysplastic syndromes. Leukemia 4:193-202, 1990.
196. Schipperus MR, Sonneveld P, Lindemans J, Vink N, Vlastuin M, Hagemeijer A, Abels J. The combined effects of IL-3, GM-CSF and G-CSF on the in vitro
197. Goselink HM, Williams DE, Fibbe WE, Wessels H, Beverstock GC, Willemze R, Falkenburg JHF. Effect of the mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells. Blood 80:750-758, 1992.
198. Willemze R, Fibbe WE, Falkenburg JHF, Kluin-Nelemans JC, Kluin PM, Landegent JE. Biology and treatment of myelodysplastic syndromes - developments in the past decade. Ann Hematol 66:107-115, 1993.
199. Merchav S, Nagler A, Fleershcer-Kurtz G. Regulatory abnormalities in the marrow of patients with myelodysplastic syndromes. Br J Haematol 73:158-163, 1988.
200. Ohmori M, Ohmori S, Ueda Y, Tohyama K, Yoshida Y, Uchino H. Myelodysplastic syndrome (MDS)-associated inhibitory activity on haemopoietic progenitor cells. Br J Haematol 74:179-184, 1990.
201. Ohmori S, Ohmori M, Yamagishi M, Okuma M. MDS-macrophage derived inhibitory activity on myelopoiesis of MDS abnormal clones, Br J Haematol 83:388-391, 1993.
202. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59:425-433, 1985.
203. Kerkhofs H, Hermans J, Haak HL, Leeksma CHW. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol 65:73-81, 1987.
204. Coiffier B, Adeleine P, Gentilhomme O, Felman P, Treille-Ritouet D, Bryon PA. Myelodysplastic syndromes. A multiparametric study of prognostic factors in 336 patients. Cancer 60:3029-3032, 1987.
205. Billström R, Thiede T, Hansen S, Heim S, Kristoffersson U, Mandahl N, Mitelman F. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes. Eur J Haematol 41:341, 1988.
206. Goasguen JE, Garand R, Bizet M et al. Prognostic factors of myelodysplastic syndromes - A simplified 3-D scoring system. Leuk Res 14:255-260, 1990.
207. Juneja SK, Imbert M, Jouault H, Scoazec J-Y, Sigaux F, Sultan C. Hematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases. J Clin Pathol 36:1129-1135, 1983.
208. Van der Weide M, Sizoo W, Nauta JJP, Krefft J, Langenhuijsen MMAC. Myelodysplastic syndromes: analysis of clinical and prognostic features in 96 patients. Eur J Haematol 41:115-122, 1988.
209. García S, Sanz MA, Amigó V et al. Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases. Am J Hematol 27:163-168, 1988.
210. Weisdorf DJ, Oken MM, Johnson GJ, Rydell RE. Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia. Br J Haematol 55:691-700, 1983.
211. Varela BL, Chuang C, Woll JE, Bennett JM. Modifications in the classification of primary myelodysplastic syndromes. Hematol Oncol 3:55-63, 1985.
212. Tricot G, Vlietinck R, Boogaerts MA, Hendrickx B, De Wolf Peeters C, Van den Berghe H, Verwilghen RL. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 60:19-32, 1985.
213. Sanz GF, Sanz MA. Prognostic factors in myelodysplastic syndromes. Leuk Res 16:77-86, 1982.
214. Tricot GJ. Prognostic factors in the myelodysplastic syndromes. Leuk Res 16:109-115, 1992.
215. Mufti GJ. Primary myelodysplastic syndrome: prognostic value of FAB classification, scoring systems, bone-marrow histology and karyotypic analysis. In: Mufti GJ, Galton DAG, eds. The Myelodysplastic Syndromes. Edinburgh: Churchill Livingstone, 1991; 207-223.
216. Riccardi A, Giordano M, Giordano P et al. Prognostic parameters in myelodysplastic syndromes: a multiple regression analysis. Eur J Haematol 40:158-162, 1988.
217. Aul C, Gatterman N, Heyll A et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 6:52-59, 1992.
218. Anderson RL, Bagby GC Jr. The prognostic value of chromosomes in patients with the preleukemic syndrome (hemopoietic dysplasia). Leuk Res 6:175, 1982.
219. Tricot G, Vlietinck R, Verwilghen RL. Prognostic factors in the myelodysplastic syndromes: a review. Scand J Haematol 36(Suppl 45):107-113, 1986.
220. Seymour JF, Estey EH. The prognostic significance of Auer rods in myelodysplasia. Br J Haematol 85:67-76, 1993.
221. Mangi MH, Mufti GJ. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Leuk Res 7:627-639, 1991.
222. Orazi A, Cattoretti G, Soligo D, Luksch R, Lambertenghi-Deliliers. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment. Leukemia 7:838-847, 1993.
223. Hokland P, Kerndrup G, Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood 67:898-902, 1986.
224. Kristensen JS, Hokland P. Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. Br J Haematol 74:270-276, 1990.
225. Mittelman M, Karcher DS, Kammerman LA, Lessin LS. High Ia (HLA-DR) and low CD11b (Mol) expression may predict early conversion to leukemia in myelodysplastic syndromes. Am J Hematol 43:165-171, 1993.
226. Knapp RH, Dewald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 60:507-516, 1985.
227. Second International Workshop on Chromosomes in Leukemia 1979. Chromosomes in preleukemia. Cancer Genet Cytogenet 2:108-113, 1980.
228. Nowell PC. Cytogenetics in preleukemia. Cancer Genet Cytogenet 5:265-278, 1982.
229. Le Beau MM, Albain KS, Larson RA et al. Clinical and cytogenetic correlations in 63 patients with therapy related myelodysplastic syndromes and acute non-lymphocytic leukemias: further incidence for characteristic abnormalities of chromosome nos. 5 and 7. J Clin Oncol 4:325-345, 1986.
230. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083-1091, 1990.
231. Yunis JJ, Rydell RE, Oken MM, Arnesen MA, Mayer MG, Lobell M. Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood 67:1721-1730, 1986.
232. Tricot G, Boogaerts MA, De Wolf-Peeters C, Van den Berghe H, Verwilghen RL. The myelodysplastic syndromes: different evolution pattern based on sequential morphological and cytogenetic investigations. Br J Haematol 59:659-670, 1985.
233. Benitez J, Carbonell F, Sanchez-Fayos J, Heimpel H. Karyotypic evolution in patients with myelodysplastic syndromes. Cancer Genet Cytogenet 16:157-167, 1985.
234. Bar-Eli M, Ahuja HG, González-Cadavid N et al. Analysis of N-RAS exon-1 mutations in myelodysplastic syndromes by polymerase chain reaction and direct sequencing. Blood 73:281-283, 1989.
235. Greenberg PL. In vitro culture techniques defining biologic abnormalities in the myelodysplastic syndromes and myeloproliferative disorders. Clin Haematol 15:973-993, 1986.
236. Rosenthal DS, Moloney WC. Refractory dysmyelopoietic anemia and acute leukemia. Blood 63:314-318, 1984.
237. Oscier DG, Worsley A, Darlow S, Figes A, Williams JD, Hamblin TJ. Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score. Leuk Res 13:833-839, 1989.
238. Tennant GB, Bowen DT, Jacobs A. Colony-cluster ratio and cluster number in cultures of circulating myeloid progenitors as indicators of high-risk myelodysplasia. Br J Haematol 77:296-300, 1991.
239. Brirard A, Huret JL, Lamotte F et al. Three cases of myelodysplastic-myeloproliferative disorders with abnormal chromatin clumping in granulocytes. Br J Haematol 70:294-295, 1988.
240. Cazzola M, Barosi G, Berzuini C et al. Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. Br J Haematol 50:55-62, 1982.
241. Seigneurin D, Hollard D. Use of the tritiated thymidine-labelling index of the myeloblast-promyelocyte pool for the identification of the leukemic population in oligoblastic leukemia. Acta Haematol 66:181-186, 1981.
242. Monteccuco C, Riccardi A, Traversi E, Giordano P, Mazzini G, Ascari E. Proliferative activity of bone marrow cells in primary dysmyelopoietic (preleukemic) syndromes. Cancer 52:1190-1195, 1983.
243. Worsley A, Mufti GJ, Coplestone JA, Oscier D, Hamblin TJ. Very low-dose cytarabine for myelodysplastic syndromes and acute myeloid leukemia in the elderly. Lancet i:966, 1986.
244. Ribera JM, Cervantes F, Reverter JC, Monserrat E, Rozman C. Acute transformation of chronic myelomonocytic leukaemia: a multivariate analysis of predictive factors. Eur J Haematol 42:284-288, 1989.
245. Ganser A, Hoelzer D. Clinical course of myelodysplastic syndromes. Hematol Oncol 6:607-618, 1992.
246. Koeffler HP. Preleukemia. Clin Hematol 15:829-850, 1986.
247. Bettelheim P, Lutz D, Majdic O et al. Cell lineage heterogeneity in blast crisis of chronic myeloid leukaemia. Br J Haematol 59:395-409, 1985.
248. San Miguel JF, Tavares de Castro J, Matutes E et al. Characterization of blast cells in chronic granulocytic leukemia in transformation, acute myelofibrosis and undifferentiated leukemias. Br J Haematol 59:297-304, 1985.
249. Koeffler HP. Golde DW. Chronic myelogenous leukemia. New concepts. New Engl J Med 304:1201-1204, 1981.
250. Bakhshi A, Minowada J, Arnold A et al. Lymphoid blast crisis of chronic myelogenous leukemia represent stages in the development of b-cell precursors. New Engl J Med 309:826-831, 1983.
251. Hoyle CF, de Bastos M, Wheatley K et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 72:45-53, 1989.
252. San Miguel JF, Hernandez JM, Gonzalez R et al. Multiparameter analysis of blast cells in patients with acute leukemia following a primary myelodysplastic syndrome. Recent results. Cancer Res 131:393-400, 1993.
253. Barton JC, Conrad ME, Parmley RT. Acute lymphoblastic leukaemia in idiopathic refractory sideroblastic anemia: evidence for common lymphoid and myeloid progenitor cell. Am J Hematol 9:109-115, 1980.
254. Berneman ZN, Van Bocktaele D, De Meyer P et al. A myelodysplastic syndrome preceding acute lymphoblastic leukaemia. Br J Haematol 60:353-354, 1985.
255. Ascensao JL, Kay NE, Wright JJ et al. Lymphoblastic transformation of myelodysplastic syndrome. Am J Hematol 22:431-434, 1986.
256. Nagler A, Brenner B, Tatarsky I. Secondary refractory anemia with excess of blasts in transformation as acute lymphoblastic leukemia. Acta Haematol 76:164-165, 1986.
257. Eridani S, Chan LC, Halil O, Pearson TC. Acute biphenotypic leukaemia (myeloid and null-ALL type) supervening in a myelodysplastic syndrome. Br J Haematol 61:525-529, 1985.
258. Hehlmann R, Zonnchen B, Thiel E, Walther B. Idiopathic refractory sidroachrestic anaemia (IRSA) progressing to acute mixed lymphoblastic-myelomonoblastic leukaemia. Blut 46:11-21, 1983.
259. Komatsu N, Yoshida M, Eguchi M, Akashi M, Sasaki R, Sakamoto S, Miura I. Simultaneous expression of lymphoid and myeloid phenotypes in acute leukaemia arising from myelodysplastic syndrome. Am J Haematol 28:103-106, 1988.
260. Hernandez JM, Sanchez I, Gonzalez M, Orfao A, Gonzalez-Sarmiento R, San Miguel JF. Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: phenotypic and genomic differences. Am J Hematol 43:256-258, 1993.
261. San Miguel JF, Gonzalez M, Cañizo MC et al. Leukemias with megakaryoblastic involvement: clinical hématologic and immunologic characteristics. Blood 72:402-407, 1988.
262. Hayhoe FGJ, Quaglino D. Refractoric sideroblastic anaemia and erythraemic myelosis: possible relationship and cytochemical observation. Br J Haematol 6:381, 1960.
263. Asou N, Hattori T, Matsuoka M, Kawano F, Takatsuki K. Rearrangement of T-cell antigen receptor chain gene in hematologic neoplasms. Blood 74:2707-2712, 1989.
264. Griesinger F, Greenberg JM, Kersey JH. T cell receptor gamma and delta rearrangement in hematologic malignancies. J Clin Invest 84:506-516, 1989.
265. Foa R, Casorati G, Giubelino MC et al. Rearrangements of immunoglobulin and T cell receptor beta and gamma genes are associated with terminal deoxynucleotidyl transferase expression in acute myeloid leukemia. J Exp Med 165:879-890, 1987.
266. Rovigatti U, Mirro J, Kitchingman G, Dahl G, Ochs J, Murphy S, Stass S. Heavy chain immunoglobulin gene rearrangement in acute nonlymphocytic leukemia. Blood 63:1023-1027, 1984.
267. Fontenay M, Flandrin G, Baurman H, Loiseau P, Valensi F, Daniel MT, Sigaux J. T cell receptor gene rearrangements occur predominantly in immature myeloid leukemias exhibiting lincage promiscuity. Leukemia 4:100-105, 1990.
268. Roth DG, Richman CM, Rowley JD. Chronic myelodysplastic syndrome (preleukemia) with the philadelphia chromosome. Blood 56:262-264, 1980.
269. Berrebi A, Bruck R, Shtalrid M, Chemke J. Philadelphia chromosome in idiopathic acquired sideroblastic anemia. Acta Haematol 72:343, 1985.
270. Martiat P, Ferrant A, Michaux J-L, Sokal G. Intensive chemotherapy for acute non-lymphoblastic leukemia after primary myelodysplastic syndrome. Hematol Oncol 6:299-305, 1988.
271. Gajewski JL, Ho WG, Nimer SD et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 7:1637-1645, 1989.
272. Yoshida Y, Oguma S, Uchino N, Maekawa T, Clinical features of long-term survivors of refractory myelodysplastic anemics. A Japanese cooperative study. Leuk Res 16:775-779, 1992.
273. Wattel E, Hecquet B, Grahek D et al. Long term survivors in myelodysplastic syndromes: a report on 63 cases and comparison with short and intermediate survivors. Leuk Res 17:733-739, 1993.
274. Appelbaum FR, Barrall J, Storb R et al. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 112:590-597, 1990.
275. De Witte T, Muus P, De Pauw B, Haanen C. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66:831-837, 1990.
276. Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood 67:257-267, 1986.
277. Pippard JM, Callender ST. The management of iron chelation therapy. Br J Haematol 54:503-507, 1983.
278. Jensen PD, Jensen IM, Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 80:121-124, 1992.
279. Pomeroy C, Oken M, Rydell RE, Filice GA. Infection in myelodysplastic syndromes. Am J Med 90:338-344, 1991.
280. Hoagland HC, Linman JW. Pyridoxine-responsive anemia: a preleukemic manifestation? Minn Med 55:891-895, 1972.
281. Bagby GC Jr, Gabourel JD, Linman JW. Glucocorticoid ther-apy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in vitro techniques. Ann Intern Med 92:55-58, 1980.
282. Bagby GC Jr. Mechanisms of glucocorticosteroid activity in patients with the preleukemic syndrome (hemopoietic dysplasia). Leuk Res 4:571-580, 1980.
283. Trichelli A, Gratwohl A, Wursch A et al. Late haematologic complications in severe aplastic anaemia. Br J Haematol 69:413-418, 1988.
284. DePlanque MM, Kluin-Nelemons HC, Van Krieken HFM, et al. Evolution of acquired severe aplastic anaemia to myelodysplasia and subsequent leukemia in adults. Br J Haematol 70:55-62, 1988.
285. Selleri C, Catalano L, Alfinito F et al. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 68:139-140, 1988.
286. Ticheli A, Grathwohl A, Wuersch A et al. Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 68:139-140, 1988.
287. Litzow MR, Kyle RA. Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome. Am J Haematol 32:226-229, 1989.
288. Najean Y, Pecking A. Refractory anaemia with excess of myeloblasts in the bone marrow: a clinical trial of androgens in 90 patients. Br J Haematol 37:25-33, 1977.
289. Najean Y, Pecking A. Refractory anaemia with excess of blasts cells: prognostic factors and effect of treatment with androgens or low-dose cytarabine. Results of a prospective trial in 58 patients. Cooperative Group for the Study of Aplastic and Refractory Anemias. Cancer 44:1976-1982, 1979.
290. Hurtado R, Sosa R, Majluf A, Labardini JR. Refractory anaemia (RA) type I FAB treated with oxymetholone (OXY): long-term results. Br J Haematol 85:236-237, 1993.
291. Ahn YS, Harrington WJ, Simon SR et al. Danazol for the treatment of idiopathic thrombocytopenia purpura. New Engl J Med 308:1396-1399, 1983.
292. Cines DB, Casileth PA, Kiss JE. Danazol therapy in myelodysplasia. Ann Intern Med 103:58-60, 1985.
293. Doll DC, Ringenberg QS, Yarbro JW. Danazol therapy in acquired idiopathic sideroblastic anemia. Acta Haematol 77:170-171, 1987.
294. Buzaid AC, Garewal HS, Lippman SM et al. Danazol in the treatment of myelodysplastic syndromes. Eur J Haematol 39:346-348, 1987.
295. Marini B, Bassan R, Barbui T. Therapeutic efficacy of danazol in myelodysplastic syndromes. Eur J Cancer Clin Oncol 24:1481-1489, 1988.
296. Stadtmauer EA, Casileth PA, Edelstein M et al. Danazol treatment of myelodysplastic patients. Br J Haematol 77:502-508, 1991.
297. Catalano L, Selleri C, Montuori N et al. Danazol for myelodysplastic syndromes. Br J Haematol 85:230-231, 1993.
298. Schreiber AD, Chien P, Tomaski A, Cines DB. Effect of danazol in immune thrombocytopenic purpura. New Engl J Med 316:503-508, 1987.
299. Lotem J, Sachs L. Potential pre-screening for therapeutic agents that induce differentiation in human myeloid leukemia cells. Int J Cancer 25:561-564, 1980.
300. Griffin J, Munroe D, Major P et al. Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis. Exp Hematol 10:774-781, 1982.
301. 3. Proc Natl Acad Sci USA 78:4990-4994, 1981.
302. Breitman TR, Collins SJ, Keene BR. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood 57:1000-1004, 1981.
303. Douer D, Koeffler HP. Retinoic acid: inhibition of the clonal growth of human myeloid leukemia cells. J Clin Invest 69:277-283, 1982.
304. Tanaka H, Abe E, Miyaura C et al. 1,25-Dihydroxy-cholecalcif-erol and a human myeloid leukemia cell line (HL-60). The presence of a cytosol receptor and induction of differentiation. Biochem J 204:713-719, 1982.
305. Tomida M, Yamamoto Y, Hozumi M. Stimulation by interferon of induction of differentiation of human promyelocytic leukemia cells. Biochem Biophys Res Commun 104:30-37, 1982.
306. Christman JK, Mendelsohn N, Herzog D et al. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemic cells (HL-60). Cancer Res 43:763-769, 1983.
307. 3 inhibits proliferation of human promyelocytic leukaemia (HL-60) cells and induces monocyte-macrophage differentiation in HL-60 and normal human bone marrow cells. Leuk Res 7:51-55, 1983.
308. Ball ED, Guyre PM, Shen L et al. Gamma interferon induces monocytic differentiation in the HL-60 cell line. J Clin Invest 73:1072-1077, 1984.
309. 3-induced differentiation in a human promyelo-cytic cell line (HL-60). Receptor-mediated maturation to macrophage-like cells. J Cell Biol 98:391-398, 1984.
310. Hassan HT, Rees JK. Retinoic acid alone and in combination with cytosine arabinoside induces differentiation of human myelomonocytic and monoblastic leukaemic cells. Hematol Oncol 6:39-45, 1988.
311. Stella CC, Cazzola M, Ganser A et al. Recombinant gamma-interferon induces in vitro monocytic differentiation of blast cells from patients with acute non lymphocytic leukemia and myelodysplastic syndromes. Leukemia 12:55-59, 1988.
312. Rowinsky EK, Donehower RC, Spivak JL et al. Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors. J Natl Cancer Inst 82:1926-1931, 1990.
313. Kizaki M, Koeffler HP. Differentiation-inducing agents in the treatment of myelodysplastic syndromes. Semin Oncol 19:95-105, 1992.
314. Ossenkoppele GJ, Wijermans PW, Nauta JJ, Huijgens PC, Langenhuijsen MM. Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: in vivo and in vitro cytotoxicity. Eur J Cancer 27:842-845, 1991.
315. Miller KB, Kyungmann K, Morrison FS et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III intergroup study. Ann Hematol 65:162-168, 1992.
316. Rowinsky EK, Conley BA, Jones RJ, Spivak JL, Auerbach M, Donehower RC. Hexamethylene bisacetamide in myelodysplastic syndromes: effect of five-day exposure to maximal therapeutic concentrations. Leukemia 6:526-534, 1992.
317. Hirst WJR, Mufti GJ. Management of myelodysplastic syndromes. Br J Haematol 84:191-196, 1993.
318. Greenberg BR, Durie BG, Barnett TC et al. Phase I-II study of 13-cis retinoic acid in myelodysplastic syndrome. Cancer Treat Rep 69:1369-1374, 1985.
319. 3 in the myelodysplastic syndromes. Blood 67:1154-1161, 1986.
320. Picozzi VJ Jr, Swanson GF, Morgan R, Hecht F, Greenberg PL. 13-cis retinoic acid treatment for myelodysplastic syndromes. J Clin Oncol 4:589-595, 1986.
321. Abrahm J, Besa EC, Hyzinski M et al. Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis retinoic acid in a patient with myelodysplastic syndrome: inhibition of growth of the patient's malignant monocytoid clone. Blood 67:1323-1327, 1986.
322. Kerndrup G, Bendit-Hansen K, Pedersen B, Ellegaard J, Hokland P. 13-cis retinoic acid treatment of myelodysplastic syndromes. Leuk Res 11:716, 1987.
323. Clark RE, Ismail SA, Jacobs A, Payne JH, Smith SA. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol 66:77-83, 1987.
324. Clark RE, Jacobs A, Lush CJ, Smith SA. Effect of 13-cis retinoic acid on survival of patients with myelodysplastic syndrome. Lancet i:763-765, 1987.
325. Koeffler HP, Heitjan D, Mertelsmann R et al. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood 71:703-708, 1988.
326. Leoni F, Ciolli S, Longo G et al. 13-cis retinoic acid in patients with myelodysplastic syndrome. Acta Haematol 80:8-12, 1988.
327. Tricot G. Effects of isotretinoin on survival of patients with myelodysplastic syndrome. Lancet i: 1271-1272, 1987.
328. Castaigne S, Chomienne C, Daniel MT et al. All-trans-retinoic acid as a differentiation therapy for acute promyelocytic leukemia: 1. Clinical results. Blood 76:1704-1709, 1990.
329. Aul C, Runde V, Gattermann N. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. Blood 82:2967-2974, 1993.
330. Kurzrock R, Estey E, Talpaz M. All-trans retinoid acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 11:1489-1495, 1993.
331. Ohno R, Hirano M, Kobayashi M et al. Treatment of myelodysplastic syndromes with all-trans retinoic acid. Blood 81:1152-1154, 1993.
332. Garewal HS, List A, Meyskens F et al. Phase II trial of fenretinide [N'-(4-hydroxyphenyl) retinamide] in myelodysplasia: possible retinoid-induced disease acceleration. Leuk Res 13:339-343, 1989.
333. Hast R, Lauren SAL, Reizenstein P. Absent clinical effects of retinoid acid and isoretinoin in the myelodysplastic syndrome. Hematol Oncol 7:297-301, 1989.
334. Mehta AB, Kumaran TO, Marsh GW. Treatment of advanced myelodysplastic syndrome with alfacalcidol. Lancet ii:761, 1984.
335. 3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 69:1399-1407, 1985.
336. 3. Am J Hematol 73:175-178, 1986.
337. Andreeff M, Young C, Clarkson B et al. Treatment of myelodysplastic syndromes (MDS) with hexamethylene bisacetamide (HMBA). Blood 72(Suppl 1):656A, 1988.
338. Andreeff M, Stone R, Michaeli J et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80:2604-2609, 1992.
339. Rutherford TR, Clegg JB, Weatherall DJ. K562 human leukaemic cells synthesize embryonic haemoglobin in response to haemin. Nature 280:164-165, 1979.
340. Monnette FC, Holden SA. Hemin enhances the in vitro growth of primitive erythroid progenitor cells. Blood 60:527-530, 1982.
341. Ruutu T, Volin L, Tenhumen R. Haem arginate as a treatment for myelodysplastic syndromes. Br J Haematol 65:425-428, 1987.
342. Volin L, Ruutu T, Knuutila S, Tenhunen R. Heme arginate as treatment for myelodysplastic syndromes. Leuk Res 12:423-426, 1988.
343. Timonen TT, Kauma H. Therapeutic effect of heme arginate in myelodysplastic syndromes. Eur J Hematol 49:234-238, 1992.
344. 2-interferon in the myelodysplastic syndromes: 1. Clinical results. Leukemia 1:105-107, 1987.
345. Block WL, Lowenberg B, Sizoo W et al. Disappearance of trisomy 8 after alpha-2 interferon in a patient with myelodys-plastic syndrome. New Engl J Med 318:787-788, 1988.
346. Galvani DW, Nethersell ABW, Conley JC. Ó-interferon in myelodysplasia: clinical observations and effects on NK cells. Leuk Res 12:257-262, 1988.
347. Gisslinger H, Chott A, Linkesh W, Fritz E, Ludwig H. Long-term Ó-interferon therapy in myelodysplastic syndromes. Leukemia 4:91-94, 1990.
348. Maiolo AT, Cortelezzi A, Calori R, Polli EE. Recombinant alpha-interferon as the first line therapy for high risk myelodysplastic syndromes. Leukemia 4:480-485, 1990.
349. Aul C, Gattermann N, Schneider W. Treatment of advanced myelodysplastic syndromes with recombinant-alpha-2b. Eur J Hematol 46:11-16, 1991.
350. Nand S, Ellis T, Messmore H, Fisher SG, Gaynor E, Fisher RI. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes. Leukemia 6:220-223, 1992.
351. Holcombe RF. Mini-dose interferon alpha-2a in the treatment of myelodysplasia. Leukemia 7:192-195, 1993.
352. Rosti V, Carlo-Stella C, Pedrazzoli P, Cazzola M. In vitro and in vivo effects of recombinant interferon gamma on the growth of hematopoietic progenitor cells from patients with myelodysplastic syndrome. Haematologica 74:435-440, 1989.
353. Schwarzinger I, Stain C, Bettelheim P et al. Gamma interferon in myelodysplastic syndromes: a pilot study. Oncology 47:322-326, 1990.
354. Beran M. Treatment of myelodysplastic syndromes. In: Freireich E, Kantarjian H, eds. Therapy of hematopoietic neoplasia. New York: Marcel Dekker, 1991; 35-82.
355. Yoshida Y, Hirashima K, Asano S, Takaku F. A phase-II trial of recombinant granulocyte colony-stimulating factor in the myelodysplastic syndromes,. Br J Haematol 78:378-384, 1991.
356. Stone RM, Spriggs DR, Arthur KA, Mayer RJ, Griffin J, Kufe DW. Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol 16:159-163, 1993.
357. Francis GE, Mufti GJ, Knowles SM et al. Differentiation induction in myelodysplasia and acute myeloblastic leukaemia: use of synergistic drug combinations. Leuk Res 11:971-977, 1987.
358. Hellström E, Robert KH, Gahrton G et al. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxy-vitamin D3 and retinoic acid in acute myeloid leukemia and myelodysplastic syndromes. Eur J Haematol 40:449-459, 1988.
359. Ganser A, Völkers B, Greher J et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes - a phase I-II trial. Blood 73:31-37, 1989.
360. Hellström E, Birgegard G, Lockner D, Helmers C, Wide L, Öst A. Treatment of myelodysplastic syndromes with recombinant erythropoietin. Blood 76(Suppl 1):279, 1990.
361. Verhoef G, Zachée P, Ferrant A et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann Hematol 64:16-21, 1992.
362. Rafanelli D, Grossi A, Longo G, Vannucchi AM, Bacci P, Ferrini PR. Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia 6:323-327, 1992.
363. Bessho M, Jinnai I, Matsuda A, Saito M, Hirashima K. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes. Int J Cell Cloning 8:445-458, 1990.
364. Bowen D, Culligan D, Jacobs A. The treatment of anaemia in myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 77:419-423, 1991.
365. Schouten HC, Vellenga E, van Rhenen DJ, de Woolf JTh, Coppens JW, Blijham GH. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 5:432-436, 1991.
366. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant erythropoietin in the treatment of myelodysplastic syndromes. Blood 78:1658-1663, 1991.
367. Van Kampf H, Prinsze-Postema TC, Kluin TC et al. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol 78:488-493, 1991.
368. Cazzola M, Poncho L, Begin Y et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: Results of a phase I/II clinical trial. Blood 79:29-37, 1992.
369. Depaoli L, Levis A, Isabella N et al. Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes. Hematologica 78:118-122, 1993.
370. Goy A, Belanger C, Casadevall N et al. High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome. Br J Haematol 84:232-237, 1993.
371. Rose EH, Rudmick SA, Abels RI et al. Efficacy and safety of recombinant human erythropoietin (r-HuEPO) in anemic patients with myelodysplastic syndromes. Leuk Res 15:13, 1991.
372. Mittelman M, Floru S, Djaldetti M. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Blood 80:841-846, 1992.
373. Razzano M, Caslini C, Cortelazzo S, Battistel V, Rambaldi A, Barbui T. Therapy with human recombinant erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 81:1083-1091, 1992.
374. Vadhan-Raj S, Kellagher MJ, Keating M et al. Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. New Engl J Med 317:1545-1552, 1987.
375. Antin JH, Smith BR, Holmes W, Rosenthal DS. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndromes. Blood 72:705-713, 1988.
376. Herrmann F, Lindemann A, Klein H et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 3:335-338, 1989.
377. Thompson JA, Lee DJ, Kidd P et al. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 7:629-637, 1989.
378. Dunbar CE, Sith D, Kinball J et al. Sequential treatment with recombinant human growth factors to compare activity of GM-CSF and IL3 in the treatment of primary myelodysplasia. Blood 76(Suppl 1):1631, 1990.
379. Hoelzer D, Seipelt G, Ganser A et al. The role of GM-CSF, interleukin-3 and erythropoietin in MDS. In: Gale RP, ed. Acute Myelogenous Leukemia: Progress and Controversies. New York: Wiley-Liss, 1990; 467-480.
380. Schuster MW, Larson R, Thompson JA et al. Granulocyte-macrophage colony-stimulating factor for myelodysplastic syndromes (MDS): results of a multicentre randomized controlled trial. Blood 78(Suppl 1):318, 1990.
381. Willemze R, Visani G, de Witte T et al. A randomized phase I/II study with recombinant human GM-CSF in patients (pts) with myelodysplastic syndromes at a relatively low risk of developing acute leukemia. Blood 76(Suppl 1):337, 1990.
382. Estey EH, Kurzrock R, Talpaz M et al. Effects of low doses of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 77:291-295, 1991.
383. Rosenfeld CS, Sulecki M, Evans C, Shadduck RK. Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating
384. Rose C, Wattel E, Bastion Y et al. Treatment of myelodysplastic syndromes (MDS) with low dose GM-CSF. A pilot study. Blood 82(Suppl 1):1489, 1993.
385. Kobayashi Y, Okabe T, Ozawa K et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. Am J Med 86:178-182, 1989.
386. Ohyashiki K, Ohyashiki JH, Toyama K, Takaku F. Hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony-stimulating factor. Jpn J Cancer Res 80:848-854, 1989.
387. Negrin R, Haeuber DH, Nagler A et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a phase I-II trial. Ann Intern Med 110:976-984, 1989.
388. Negrin R, Haeuber DH, Nagler A et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36-43, 1990.
389. Ganser A, Seipelt G, Lindemann A et al. Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455-462, 1990.
390. Kurzrock R, Talpaz M, Estrov Z et al. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241-1250, 1991.
391. Bernstein SH, Gilliland DG, Aster JC et al. A randomized trial of two doses of recombinant human interleukin-3 (rhIL-3) in patients with myelodysplastic syndromes (MDS). Blood 80(Suppl 1):1631, 1992.
392. Willemze R, Fanaux P, Gerhartz H et al. A randomized phase I/II multicenter study (EORTC 06891) of rhIL-3 in patients with myelodysplastic syndromes at relatively low risk of developing acute leukemia (MDS-LR). Blood 80(Suppl 1):86, 1992.
393. Ganser A, Ottmann OG, Seipelt G et al. Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes. Leukemia 7:696-701, 1993.
394. Hansen PB, Johnsen HE, Hippe E et al. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplasia. Blood 80(Suppl 1):327, 1992.
395. Hellström-Lindberg E, Birgegard G, Carlsson M et al. Treatment of myelodysplastic syndromes (MDS) with a combination of granulocyte-CSF and erythropoietin - a synergistic effect on the erythropoietic response? Blood 80(Suppl 1):326, 1992.
396. List AL, Noyes W, Power et al. Combined treatment of myelodysplastic syndromes (MDS) with recombinant human interleukin-3 (IL-3) and erythropoietin. Blood 82(Suppl 1):1491, 1993.
397. Negrin RS, Stein R, Vardiman J et al. Treatment of anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737-743, 1993.
398. Verhoef G, Demunynck H, Zachée P et al. Treatment of myelodysplastic syndromes (MDS) with the combination of interleukin-3 and erythropoietin. Blood 82(Suppl 1):1492, 1993.
399. Nand S, Sosman J, Godwin JE, Fisher RI. A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Blood 83:357-360, 1994.
400. Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4:826-834, 1990.
401. Gerhartz HH, Marcus R, Delmer A et al. Randomized phase-I/ II study with GM-CSF and low-dose Ara-C in patients with 'high-risk' myelodysplastic syndrome (MDS). Blood 76(Suppl 1):274, 1990.
402. Hoelzer D, Ganser A, Ottmann OG et al. Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes. Haematol Blood Transfus 33:763-769, 1990.
403. Estey E, Thall P, Anfreef M et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671-678, 1994.
404. Baccarani M, Tura S. Differentiation of myeloid leukaemic cells: new possibilities for therapy. Br J Haematol 42:485-490, 1979.
405. Castaigne S, Daniel MT, Tilly H et al. Does treatment with Ara-C in low-dosage cause differentiation of leukemic cells? Blood 62:85-86, 1983.
406. Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4:1857-1864, 1986.
407. Baccarani M, Zaccaría A, Bandini G et al. Low-dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia. Leuk Res 7:539-545, 1983.
408. Wisch JS, Griffin JD, Kyle DW. Response of preleukemic syndromes to continuous infusion of low-dose cytarabine. New Engl J Med 309:1599-1603, 1983.
409. Mufti GJ, Oscier DG, Hamblin TJ et al. Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. New Engl J Med 309:1653-1654, 1983.
410. Jehn U, DeBrock R, Haanen C. Clinical trial of low-dose Ara-C in the treatment of acute leukemia and myelodysplasia. Blut 48:255-261, 1984.
411. Tricot G, DeBock R, Dekker AW et al. Low-dose cytosine arabinoside (Ara-C) in myelodysplastic syndromes. Br J Haematol 58:231-240, 1984.
412. Winter JN, Variakolis D, Gaynor ER. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer 56:443-449, 1985.
413. Bolwell R, Cassileth P, Gale P. Low-dose cytosine arabinoside in myelodysplasia and acute myeloid leukemia - a review. Leukemia 2:575-579, 1987.
414. Fridik MA, Wahl G, Herbinger W. Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation. Blut 57:357-360, 1988.
415. Powell BL, Capizzi RL, Jackson DV et al. Low-dose Ara-C for patients with myelodysplastic syndromes. Leukemia 2:153-156, 1988.
416. Aul C, Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 64:1812-1818, 1989.
417. Hellström-Linberg E, Robert K-H, Gahrton G et al. A predictive model for the clinical response to low-dose Ara-C: a study of 102 patients with myelodysplastic syndrome or acute leukaemia. Br J Haematol 81:503-511, 1992.
418. Cheson BD, Simon R. Low-dose ara-C in acute non-lymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Semin Oncol 14(Suppl 1):126-133, 1987.
419. Aul C, Gattermann N. The role of low-dose chemotherapy in myelodysplastic syndromes. Leuk Res 16:207-215, 1992.
420. Preisler HD, Raza A, Barcos M et al. High-dose cytosine arabinoside in the treatment of preleukemic disorders: a Leukemia Intergroup study. Am J Hematol 23:131-134, 1986.
421. Silverman LR, Holland JF, Nelson D et al. Trilineage response of myelodysplastic syndromes to subcutaneous azacytidine. Proc Am Soc Clin Oncol 10:22, 1991.
422. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T. Evaluation of continuous-infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 37:100-104, 1991.
423. Silverman LR, Holland JF, Weinberg RS et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7(Suppl 1):21-29, 1993.
424. Harada M, Shibuya T, Teshima T et al. A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes. Leuk Res 17:629-632, 1993.
425. De Bock R, Van Hoof A, Van Hove W et al. Oral idarubicin (IDA) for RAEB, RAEBt and acute leukemia (AL) post myelodysplastic syndrome (MDS). A phase II open study. Proc Am Soc Clin Oncol 8:204, 1989.
426. Lowenthal RM, Lambertenghi-Deliliers G. Oral idarubicin as treatment for advanced myelodysplastic syndromes. Hematologica 76:398-401, 1991.
427. Greenberg BR, Reynolds RD, Charron CB et al. Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I-II study. Cancer 71:1989-1992, 1993.
428. Feldman E, Sullivan P, Ahmed T et al. Phase II trial of homoharringtonine (HHT) in patients with myelodysplastic syndromes (MDS). Blood 72(Suppl 1):198, 1988.
429. Oscier DG, Worsley A, Hamblin TJ. Treatment of chronic myelomonocytic leukaemia with low dose etoposide. Br J Haematol 72:468-471, 1989.
430. Ogata K, Yamada T, Ito T et al. Low-dose etoposide: a potential therapy for myelodysplastic syndromes. Br J Haematol 82:354-357, 1992.
431. Martinez J, Martin G, Sanz GF et al. A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia. J Clin Oncol 9:39-43, 1991.
432. Mertelsmann R, Thaler HT, To L et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56:773-781, 1980.
433. Armitage JO, Dick FR, Needelman SW et al. Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 65:601-605, 1981.
434. Tricot G, Boogaerts MA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 63:477-483, 1986.
435. Michels S, Saumur J, Arthur D, Robinson L, Brunning R. Refractory anemia with excess of blasts in transformation. Hematologic and clinical study of 52 patients. Cancer 64:2340-2346, 1989.
436. Aul C, Schneider W. Treatment of advanced myelodysplastic syndromes: trend towards more aggressive chemotherapy? Haematol Blood Transfus: Acute Leukemias II 33:382-386, 1990.
437. Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497-501, 1991.
438. Keating MJ, McCredie KB, Benjamin RS et al. Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine and prednisone (ROAP). Blood 58:584-591, 1981.
439. Babapulle FB, Catovsky D, Galton DAG. Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia. Br J Haematol 66:445-450, 1987.
440. Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA. Multidrug resistance in haematopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 72:40-44, 1989.
441. List AF, Spier CM, Cline A et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 78:28-34, 1991.
442. Appelbaum FM, Storb, Ramberg RE et al. Treatment of preleukemic syndromes with marrow transplantation. Blood 69:92-96, 1987.
443. O'Donnell MR, Nademanee AP, Synder DS et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 5:1822-1826, 1987.
444. Belanger R, Gyger M, Perrault C, Bonny Y, St-Louis J. Bone marrow transplantation for myelodysplastic syndromes. Br J Haematol 69:29-33, 1988.
445. Bunin NJ, Casper JT, Chitambar C et al. Partially matched marrow transplantation in patients with myelodysplastic syndromes. J Clin Oncol 6:1851-1855, 1988.
446. Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH. Bone marrow transplantation for myelodysplasia and acute nonlymphoblastic leukemia. J Clin Oncol 8:1707-1714, 1990.
447. Ratanatharathorn V, Chatchada K, Uberti J et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81:2194-2199, 1993.
448. De Witte T, Zwaan F, Hermans J et al. Allogeneic bone marrow transplantation for secondary leukemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74:151-155, 1990.
449. Marmont AM, Horowitz MM (for the International Bone Marrow Transplantation Registry [IBMTR]). Outcome of bone marrow transplantation for myelodysplastic syndromes. Bone Marrow Transplant 5(Suppl 2):71, 1990.
450. De Witte T, Hermans J, van Biezen A et al. Prognostic variables in bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes: a survey of the working party on leukaemia. Bone Marrow Transplant 7(Suppl 2):40, 1991.
451. Sutton L, Leblond V, Le Maignan C et al. Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients. Bone Marrow Transplant 7(Suppl 2):39, 1991.
452. Anderson JE, Appelbaum FR, Lloyd D et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82:677-681, 1993.
453. De Witte T, Gratwohl A. Bone marrow transplantation for myelodysplastic syndromes and secondary leukaemias. Br J Haematol 84:361-364, 1993.
454. Nevill TJ, Shepherd JD, Reece DE et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 10:445-450, 1992.
455. Laporte JP, Isnard F, Lesage S et al. Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. Leukemia 7:2030-2033, 1993.
456. Woods WG, Kobrinsky N, Buckley J et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. J Clin Oncol 11:1448-1457, 1993.
457. Oberg G, Simmonson B, Smedmyr B et al. Is haematological reconstitution seen after ABMT in MDS patients? Bone Marrow Transplant 4(Suppl 2):52, 1989.
458. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New Engl J Med 328:593-599, 1993.